Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 54-year-old man who underwent an orthotopic heart transplant six months ago is admitted to the hospital with hemoptysis, pleuritic chest pain, and a low-grade fever. His maintenance immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Chest computed tomography reveals a right upper lobe dense consolidation with a surrounding halo of ground-glass opacity. Serum galactomannan testing is markedly positive, establishing a diagnosis of invasive pulmonary aspergillosis. The infectious disease service recommends initiating intravenous posaconazole therapy immediately.

Which of the following treatment modifications and monitoring strategies are indicated for this patient upon starting the antifungal therapy? (Select two)

  1. Decrease the daily dose of tacrolimus empirically.Answer
  2. Perform serial electrocardiograms to monitor the QTc interval.Answer
  3. C
    Delay the initiation of posaconazole until a bronchoscopy with bronchoalveolar lavage confirms the diagnosis.
  4. D
    Defer therapeutic drug monitoring of tacrolimus until posaconazole reaches steady state.
  5. E
    Discontinue mycophenolate mofetil preemptively to prevent synergistic bone marrow suppression.

Answer

The correct strategies are to decrease the daily dose of tacrolimus empirically and to perform serial electrocardiograms to monitor the QTc interval.
Posaconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor that is heavily metabolized by CYP3A4. Coadministration leads to significantly elevated tacrolimus levels, greatly increasing the risk of acute nephrotoxicity and neurotoxicity. Standard of care requires a preemptive, empiric reduction in the tacrolimus dose (often by one-third to one-half) when starting an azole antifungal. Furthermore, both posaconazole and tacrolimus are known to cause QTc interval prolongation. Their concomitant use creates an additive risk for malignant arrhythmias, mandating serial electrocardiogram (ECG) monitoring.

Step-by-Step Solution

1
Evaluate the proposed new medication (posaconazole) for pharmacokinetic interactions with the patient's current immunosuppressive regimen.
Posaconazole is identified as a strong inhibitor of the CYP3A4 enzyme, which is responsible for the metabolism of tacrolimus.
Preventing acute calcineurin inhibitor toxicity (such as severe nephrotoxicity and neurotoxicity) requires anticipating impaired clearance of the drug.
2
Assess for overlapping or additive toxicities between the patient's current medications and posaconazole.
Both tacrolimus and posaconazole are recognized as medications that can independently prolong the QTc interval.
Recognizing additive adverse effect profiles is crucial to prevent life-threatening arrhythmias, such as Torsades de Pointes.
3
Implement a safe initiation and monitoring strategy.
Empirically reduce the tacrolimus dose, start posaconazole without delay, and order serial ECGs for the duration of concurrent therapy.
This comprehensively balances the need for life-saving antifungal therapy with the severe risks of immunosuppressant toxicity and malignant arrhythmias.

Key Concept

Management of pharmacokinetic interactions and overlapping toxicities when initiating azole antifungals in solid organ transplant recipients.
Estimated Time:2m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic